J Hypertens. 2022 Jun 1;40(Suppl 1):e314. doi: 10.1097/01.hjh.0000838808.45705.35.
ABSTRACT
OBJECTIVE: To evaluate the effects of Sacubitril-Valsartan on early renal function and vascular function in patients during perimenopause with hypertension.
DESIGN AND METHOD: This study was a prospective, randomized, positive control and open label test. The subjects were 427 perimenopausal women (30-65 years old) with mild or moderate hypertension who were treated in the Department of Cardiovascular Medicine of the Second Hospital of Lanzhou University. They were randomly assigned to Sacubitril-Valsartan group (n = 165) or valsartan group (n = 262) for 24 weeks. Renal function, urinary renal function and vascular function were evaluated at baseline and 24 weeks after treatment.
RESULTS: There was no significant difference in the clinical baseline data between patients with sacubitril-valsartan and patients with valsartan (P> 0.05). Comparison of the systolic blood pressure (oSBP) and diastolic blood pressure(oDBP)before and after treatment: the baseline vs. 24-week difference between the sacubitril-valsartan group and the valsartan group was statistically significant (p < 0.001). The carotid-femoral pulse wave velocity (cfPWV) in the vascular function indexes of the sacubitril-valsartan group was significantly improved (p < 0.001). The improvement of valsartan group was not obvious. Other vascular function parameters such as cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI) were not significantly improved in the two groups. Urinary microalbumin (MAU)was significantly improved in both blood renal function and urine renal function. The improvement was observed in the sacubitril-valsartan group (p < 0.001) and valsartan group (p = 0.027), but the improvement was stronger in the sacubitril-valsartan group (p < 0.001).
CONCLUSIONS: Sacubictril-valsartan has a stronger antihypertensive effect than valsartan in patients during perimenopause with hypertension, and can improve MAU and cfPWV in patients.
PMID:36027471 | DOI:10.1097/01.hjh.0000838808.45705.35
